Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Abstract readRandomized Controlled TrialClinical Trial, Phase IIIComparative Study
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.Advances in therapy · 2026Pooled it
- An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.Blood advances · 2026Trial
- Beyond Frailty Scores: Unmet Needs and Tailored Treatment Strategies in Patients With Chronic Lymphocytic Leukemia Aged ≥ 80 Years.European journal of haematology · 2026Review
- Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.Blood advances · 2026Article
- Article
- Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Management.Journal of clinical medicine · 2026Review
- Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.Internal medicine journal · 2026Article
- Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States.Future oncology (London, England) · 2026Article
- From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.European journal of haematology · 2026Review
- First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.European journal of haematology · 2026Article
- Surrogate Endpoints in CLL: From Promise and Pitfalls to a Context-Specific Validation Framework.Hematology reports · 2026Review
- Missing Data Handling in the Application of Matching-Adjusted Indirect Comparison.Therapeutic innovation & regulatory science · 2026Article
- Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting.Journal of hematology & oncology · 2026Article
- Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.European journal of haematology · 2026Article
- Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.HemaSphere · 2026Article
- A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia.Oncology and therapy · 2026Review
- A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.Oncology and therapy · 2026Article
- Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa.Applied health economics and health policy · 2026Article
- Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.Cancer · 2026Article
- Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.Blood advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Mazyar ShadmanFred Hutchinson Cancer Center, University of Washington, Seattle, WA.ORCID 0000-0002-3365-6562
Talha MunirHaematology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Tadeusz RobakCopernicus Memorial Hospital, Medical University of Łódź, Łódź, Poland.ORCID 0000-0002-3411-6357
Jennifer R BrownDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2040-4961
Brad S KahlSiteman Cancer Center, Washington University School of Medicine, St Louis, MO.ORCID 0000-0003-0459-6609
Paolo GhiaUniversità Vita-Salute San Raffaele, Milano, Italy.ORCID 0000-0003-3750-7342
Krzysztof GiannopoulosExperimental Hematooncology Department, Medical University of Lublin, Lublin, Poland.ORCID 0000-0003-0135-4030
Martin Šimkovič4th Department of Internal Medicine-Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic.ORCID 0000-0003-0331-5334
Anders ÖsterborgDepartment of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.
Luca LaurentiFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Patricia A WalkerPeninsula Health and Peninsula Private Hospital, Frankston, Melbourne, VIC, Australia.
Stephen S OpatLymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.ORCID 0000-0002-0308-6458
Hanna CiepluchDepartment of Hematology, Copernicus Regional Oncology Centre, Gdansk, Poland.
Richard GreilThird Medical Department With Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.ORCID 0000-0002-4462-3694
Merit HannaDepartment of Haematology, Waitemata District Health Board, Takapuna, New Zealand.
Monica TaniHematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy.
Marek TrněnýFirst Department of Medicine, First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic.ORCID 0000-0002-6952-6073
Danielle BranderHematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC.ORCID 0000-0002-9581-2807
Ian W FlinnTennessee Oncology/OneOncology, Nashville, TN.ORCID 0000-0001-6724-290X
Sebastian GrosickiDepartment of Hematology and Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland.
Emma VernerConcord Repatriation General Hospital, Concord, NSW, Australia.ORCID 0009-0004-4945-2574
Alessandra TedeschiDepartment of Hematology, Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Sophie de GuibertHôpital de Pontchaillou, Rennes, France.
Gayane TumyanDepartment of Chemotherapy of Hemoblastosis, Blokhin Russian Cancer Research Center, Moscow, Russia.
Kamel LaribiHematology Department, Centre Hospitalier du Mans, Le Mans, France.ORCID 0000-0001-5589-7570
José A García-MarcoUnidad de Citogenetica Molecular, Servicio de Hematología, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Jian-Yong LiThe First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Tian TianBeiGene USA, Inc, San Mateo, CA.
Yu LiuBeiGene USA, Inc, San Mateo, CA.
Roman KorolkiewiczBeiGene USA, Inc, San Mateo, CA.
Andy SzetoBeiGene USA, Inc, San Mateo, CA.ORCID 0000-0002-9195-6520
Constantine S TamAlfred Health and Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-9759-5017
Wojciech JurczakMaria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideLeukemia, Lymphocytic, Chronic, B-CellPiperidinesPyrazolesPyrimidinesRituximabAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedProgression-Free SurvivalBendamustine HydrochloridePiperidinesPyrazolesPyrimidinesRituximabzanubrutinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.